Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review

Estrella Immunopharma (ESLA) announced that an independent Data Safety Monitoring Board has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the safety profile observed, the DSMB recommended advancing the trial to Phase II, or the expansion phase, at the Recommended Phase II Dose. The expansion phase will further evaluate the safety and preliminary efficacy of EB103, the company’s CD19-redirected Artemis T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma. In the Phase I dose escalation phase, no treatment-related serious adverse events were reported. The high-dose cohort achieved a 100% complete response rate at Month 1 in all evaluable patients.